Patents by Inventor Naoki Tarui
Naoki Tarui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10308605Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug therType: GrantFiled: August 1, 2014Date of Patent: June 4, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Publication number: 20140343070Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug theType: ApplicationFiled: August 1, 2014Publication date: November 20, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Patent number: 8361968Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: GrantFiled: June 29, 2011Date of Patent: January 29, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Chieko Kitada, Taiji Asami, Naoko Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto
-
Publication number: 20120015868Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: June 29, 2011Publication date: January 19, 2012Applicant: Takeda Pharmaceutical Company LimitedInventors: Chieko Kitada, Taiji Asami, Naoko Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Publication number: 20110028476Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof.Type: ApplicationFiled: September 1, 2010Publication date: February 3, 2011Inventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Patent number: 7795267Abstract: The present invention provides a compound represented by the formula: wherein R1 is —(C?O)—NR7R8 or —(C?O)—OR6, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.Type: GrantFiled: August 26, 2004Date of Patent: September 14, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Kohji Fukatsu, Yutaka Nakayama, Naoki Tarui, Masaaki Mori, Hirokazu Matsumoto, Osamu Kurasawa, Hiroshi Banno
-
Publication number: 20090318365Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivatives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: June 2, 2009Publication date: December 24, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Chieko Kitada, Taiji Asami, Naoko Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Patent number: 7622487Abstract: The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R1 is not a methyl group, and when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.Type: GrantFiled: May 29, 2003Date of Patent: November 24, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Yoshinori Ikeura, Tadatoshi Hashimoto, Naoki Tarui, Junya Shirai
-
Publication number: 20090275568Abstract: The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.Type: ApplicationFiled: July 7, 2009Publication date: November 5, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Nicholas William Hird, Naoki Tarui, Hiroshi Banno, Yasuhiko Kawano, Nobuhiro Inatomi
-
Publication number: 20090270625Abstract: The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; — --- represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.Type: ApplicationFiled: June 2, 2009Publication date: October 29, 2009Applicant: Takeda Pharmaceutical Company LimtedInventors: Masahiro Kajino, Nicholas William Hird, Naoki Tarui, Hiroshi Banno, Yasuhiko Kawano, Nobuhiro Inatomi
-
Publication number: 20090258893Abstract: The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.Type: ApplicationFiled: June 2, 2009Publication date: October 15, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Nicholas William Hird, Naoki Tarui, Hiroshi Banno, Yasuhiko Kawano, Nobuhiro Inatomi
-
Publication number: 20080220445Abstract: The present invention provides a screening method for a compound inhibiting a transmembrane enzyme activity by binding to a transmembrane region of the enzyme, characterized by using (a) a protein having a part or all of an amino acid sequence of the enzyme, comprising a region comprising an active center and a part or all of a transmembrane region of the transmembrane enzyme, and optionally (b) a protein having a part of an amino acid sequence of the transmembrane enzyme, comprising the region comprising the active center and lacking the above-mentioned part or all of the transmembrane region, and measuring the binding of a test substance to each protein and the enzyme activity of each protein, as well as a kit for screening comprising the above-mentioned protein of (a) and (b).Type: ApplicationFiled: September 30, 2005Publication date: September 11, 2008Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventor: Naoki Tarui
-
Publication number: 20080139639Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof.Type: ApplicationFiled: September 30, 2005Publication date: June 12, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi
-
Publication number: 20080039452Abstract: The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.Type: ApplicationFiled: April 28, 2005Publication date: February 14, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Nicholas Hird, Naoki Tarui, Hiroshi Banno, Yasuhiko Kawano, Nobuhiro Inatomi
-
Publication number: 20070072865Abstract: The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.Type: ApplicationFiled: August 26, 2004Publication date: March 29, 2007Inventors: Kohji Fukatsu, Yutaka Nakayama, Naoki Tarui, Masaaki Mori, Hirokazu Matsumoto, Osamu Kurasawa, Hiroshi Banno
-
Publication number: 20060252797Abstract: A compound having a partial structure represented by the formula (A) (wherein ring Xa represents a nitrogen-containing ring and R represents optionally substituted amino) or a salt thereof. The compound or salt is highly effective in regulating neuromedin U receptors and is useful as a preventive/therapeutic agent for hypertension, etc.Type: ApplicationFiled: November 5, 2003Publication date: November 9, 2006Inventors: Masahiro Kajino, Shuji Hinuma, Naoki Tarui, Toshiro Yamashita, Yutaka Nakayama
-
Publication number: 20060241051Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: December 26, 2003Publication date: October 26, 2006Inventors: Chieko Kitada, Taiji Asami, Naoki Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Patent number: 7091247Abstract: A novel biphenyl compound having GPR 14 antagonistic activity. It is a compound represented by the formula (I): wherein R1 represents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc., R2 and R3 each represents a hydrocarbon group, etc.; and rings B and C each represents an optionally further substituted benzene ring, or a salt thereof.Type: GrantFiled: June 28, 2001Date of Patent: August 15, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Naoki Tarui, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Tetsuo Miwa, Shiro Takekawa
-
Patent number: 7087597Abstract: Compounds of the formula wherein R1, R2, R3, R4, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.Type: GrantFiled: October 11, 2000Date of Patent: August 8, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Tetsuo Miwa, Mitsuo Yamamoto, Takayuki Doi, Naoki Tarui
-
Publication number: 20060167052Abstract: The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R1 is not a methyl group, and 15 when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.Type: ApplicationFiled: May 29, 2003Publication date: July 27, 2006Inventors: Yoshinori Ikeura, Tadatoshi Hashimoto, Naoki Tarui, Junya Shirai, Masayuki Yamashita